Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection

Table 2

IL28B rs12979860 variant frequencies in blood donors and patients with HCV infection and different outcomes. Caucasian individuals reported in literature (PubMed), 2009–2013.

	Blood donors; (HCV neg.)	Spontaneous clearance of HCV	HCV patients					HCV patients total
			Chronic HCV	Mild/moderate fibrosis	Cirrhosis	Hepatocellular carcinoma	Mixed cryoglobulinemia S.
	Number (%)	Number (%)	Number (%)	Number (%)	Number (%)	Number (%)	Number (%)	Number (%)
IL28B genotype
CC	631 (46.2)	273 (68.8)	1004 (39.6)	212 (31.9)	126 (31.6)	6 (17.1)	99 (39.6)	1447 (37.3)
CT	599 (43.8)	102 (25.7)	1225 (48.3)	373 (56.2)	204 (51.1)	21 (60.0)	113 (45.2)	1936 (49.9)
TT	136 (10.0)	22 (5.5)	305 (12.0)	79 (11.9)	69 (17.3)	8 (22.8)	38 (15.2)	499 (12.8)
Total	1366 (100.0)	397 (100.0)	2534 (100.0)	664 (100.0)	399 (100.0)	35 (100.0)	250 (100.0)	3882 (100.0)
𝜒^2 (𝑃 value)^a	—	Ref.	118.8 (<0.001)	135.9 (<0.001)	112.4 (<0.001)	40.5 (<0.001)	55.7 (<0.001)	148.9 (<0.001)
IL28B dominant model
CC	631 (46.2)	273 (68.8)	1004 (39.6)	212 (31.9)	126 (31.6)	6 (17.1)	99 (39.6)	1447 (37.3)
CT + TT	735 (53.8)	124 (31.2)	1530 (60.4)	452 (68.1)	273 (68.4)	29 (82.9)	151 (60.1)	2435 (62.7)
Total	1366 (100.0)	397 (100.0)	2534 (100.0)	664 (100.0)	399 (100.0)	35 (100.0)	250 (100.0)	3882 (100.0)
𝜒^2 (𝑃 value)^a	—	Ref.	118.6 (<0.001)	135.9 (<0.001)	110.1 (<0.001)	37.5 (<0.001)	53.4 (<0.001)	148.6 (<0.001)
IL28B allele
C	1861 (68.1)	648 (81.6)	3233 (63.8)	797 (60.0)	456 (57.1)	33 (47.1)	311 (62.2)	4830 (62.2)
T	871 (31.9)	146 (18.4)	1835 (36.2)	531 (40.0)	342 (42.9)	37 (52.9)	189 (37.8)	2934 (37.8)
Total	2732 (100.0)	794 (100.0)	5068 (100.0)	1328 (100.0)	798 (100.0)	70 (100.0)	500 (100.0)	7764 (100.0)
𝜒^2 (𝑃 value)^a	—	Ref.	97.4 (<0.001)	106.7 (<0.001)	112.1 (<0.001)	45.8 (<0.001)	60.3 (<0.001)	117.7 (<0.001)

aPearson’s chi-square with spontaneous clearance of HCV as reference group.